ICCVAM Recommends Non-animal Endocrine Disruptor Screening

Posted: February 20, 2012

page 2 of 2

The ICCVAM evaluation is detailed in a report "ICCVAM Test Method Evaluation Report: The Lumi-Cell ER (BG1Luc ER TA) Test Method: An In Vitro Assay for Identifying Human Estrogen Receptor Agonist and Antagonist Activity of Chemicals (NIH Publication No. 11-7850)." The report also provides performance standards that can be used to evaluate functionally and mechanistically similar test methods, recommended test method protocols, a final background review document describing the current validation status of this test method and recommendations for future studies.

The ICCVAM report and recommendations have been transmitted to federal agencies for their review and response to ICCVAM in accordance with the provisions of the ICCVAM Authorization Act of 2000, which requires agencies to review the recommendations and respond to ICCVAM within 180 days. The BG1Luc ER TA test method was adapted to a high-throughput format using 1536-well plates by the National Institutes of Health (NIH) Center for Translational Therapeutics (NCTT; formerly the NIH Chemical Genomics Center). Preliminary results are promising, and it is expected that this method will be incorporated into the Tox21 screening paradigm in 2012.